GlassScriptPhysician profile
Troy J Ostrander
NPI 1437383718
$2,077.17
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $345 · 2021: $936 · 2022: $211.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $203.00 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $189.09 | 2019-2022 | |
| Amarin Pharma, INC. | $174.23 | 2021 | |
| Glaxosmithkline, LLC. | $168.22 | 2020-2022 | |
| Amgen INC. | $143.70 | 2019-2021 | |
| Abbvie INC. | $140.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $112.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.04 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.44 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $91.41 | 2019-2021 | |
| Mylan Specialty L.P. | $80.06 | 2019-2020 | |
| Lilly USA, LLC | $76.36 | 2019-2021 | |
| Allergan, INC. | $61.55 | 2019-2020 | |
| Abbott Laboratories | $56.94 | 2022 | |
| Orexo US, INC. | $54.07 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $50.29 | 2019-2021 | |
| Melinta Therapeutics, LLC | $44.84 | 2019-2020 | |
| Astellas Pharma US INC | $38.36 | 2021 | |
| Avanir Pharmaceuticals, INC. | $30.46 | 2020-2021 | |
| Mdd US Operations, LLC | $27.28 | 2019 | |
| Bausch Health US, LLC | $19.19 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.00 | 2021 | |
| Pacira Therapeutics, INC. | $17.18 | 2019 | |
| Indivior INC. | $16.57 | 2019 | |
| Xeris Pharmaceuticals, INC. | $15.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.99 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $13.19 | 2020 | |
| Esperion Therapeutics, INC. | $12.78 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $11.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Ostrander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.